Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K981639
    Manufacturer
    Date Cleared
    1998-09-03

    (118 days)

    Product Code
    Regulation Number
    866.1640
    Reference & Predicate Devices
    N/A
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    For in vitro diagnostic use:

    System U3™ is a qualitative technique for antimicrobial susceptibility testing of nonfastidious Gram negative and Gram positive aerobic bacteria, such as Enterobacteriaceae, Pseudomonas, Staphylococcus and Enterococcus species. The system comprises an antibiotic gradient with MIC break-point concentrations and is used to determine the susceptibility categories of microorganisms to different antimicrobial agents, as tested on agar media using overnight incubation.

    This 510(k) application is for System U3/Ciprofloxacin susceptibility testing based on the MIC breakpoints of Susceptible ≤ 1 ug/ml, Intermediate 2 ug/ml and Resistant ≥ 4 µg/ml for use with non-fastidious Gram negative and Gram positive aerobic bacteria.

    Device Description

    System U3™ is a qualitative technique for antimicrobial susceptibility testing of nonfastidious Gram negative and Gram positive aerobic bacteria, such as Enterobacteriaceae, Pseudomonas, Staphylococcus and Enterococcus species. The system comprises an antibiotic gradient with MIC break-point concentrations and is used to determine the susceptibility categories of microorganisms to different antimicrobial agents, as tested on agar media using overnight incubation.

    AI/ML Overview

    The provided text is a 510(k) clearance letter from the FDA for a device called "System U3™ for Ciprofloxacin." It does not contain the detailed study information required to answer the questions about acceptance criteria, device performance, sample sizes, ground truth establishment, or expert qualifications.

    The letter explicitly states that the device is "substantially equivalent" to legally marketed predicate devices. This means that instead of providing a new study that meets specific acceptance criteria, the manufacturer demonstrated that their device performs similarly to an already approved device. The letter focuses on regulatory approval rather than a detailed performance study.

    Therefore, I cannot provide the requested information from the given text. A typical 510(k) clearance letter does not include the specifics of a clinical validation study. These details would be in the full 510(k) submission, which is not provided here.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1